Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.